Agios Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 02, 2023 at 09:21 am EDT
Share
Agios Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 7.4 million compared to USD 3.52 million a year ago. Net loss was USD 91.32 million compared to USD 81.75 million a year ago. Basic loss per share from continuing operations was USD 1.64 compared to USD 1.49 a year ago.
For the nine months, revenue was USD 19.72 million compared to USD 9.93 million a year ago. Net loss was USD 256.15 million compared to USD 268.33 million a year ago. Basic loss per share from continuing operations was USD 4.61 compared to USD 4.9 a year ago.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
AGIOS PHARMACEUTICALS, INC. 
